151 related articles for article (PubMed ID: 7562403)
21. Oral colon targeted delivery systems for treatment of inflammatory bowel diseases: synthesis, in vitro and in vivo assessment.
El-Kamel AH; Abdel-Aziz AA; Fatani AJ; El-Subbagh HI
Int J Pharm; 2008 Jun; 358(1-2):248-55. PubMed ID: 18502065
[TBL] [Abstract][Full Text] [Related]
22. [Study on the enzyme dependant colon targeting prodrug--dexamethasone succinate dextran and its tablets].
Pang YN; Zhang ZR; Pang QJ; Li TL
Yao Xue Xue Bao; 2001 Aug; 36(8):625-30. PubMed ID: 12579944
[TBL] [Abstract][Full Text] [Related]
23. Oral budesonide for induction of remission in ulcerative colitis.
Sherlock ME; Seow CH; Steinhart AH; Griffiths AM
Cochrane Database Syst Rev; 2010 Oct; (10):CD007698. PubMed ID: 20927762
[TBL] [Abstract][Full Text] [Related]
24. Macromolecular prodrug of 4-aminosalicylic acid for targeted delivery to inflamed colon.
Vadnerkar G; Dhaneshwar S
Curr Drug Discov Technol; 2013 Mar; 10(1):16-24. PubMed ID: 22725691
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis.
Kolkman JJ; Möllmann HW; Möllmann AC; Penã AS; Greinwald R; Tauschel HD; Hochhaus G
Drugs Today (Barc); 2004 Jul; 40(7):589-601. PubMed ID: 15510233
[TBL] [Abstract][Full Text] [Related]
26. Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
Li F; Wu G; Zheng H; Wang L; Zhao Z
Eur J Med Chem; 2016 Jan; 108():486-494. PubMed ID: 26717200
[TBL] [Abstract][Full Text] [Related]
27. Delivery of glucocorticoid conjugate in rat gastrointestinal tract and its treatment for ulcerative colitis.
Zhou SY; Mei QB; Liu L; Guo X; Qiu BS; Zhao DH; Cho CH
Acta Pharmacol Sin; 2001 Aug; 22(8):761-4. PubMed ID: 11749853
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic switching of sulpiride, an anti-psychotic and prokinetic drug, to an anti-colitic drug using colon-specific drug delivery.
Kim D; Kim W; Jeong S; Kim D; Yoo JW; Jung Y
Drug Deliv Transl Res; 2019 Feb; 9(1):334-343. PubMed ID: 30426357
[TBL] [Abstract][Full Text] [Related]
29. Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice.
Xian S; Zhu J; Wang Y; Song H; Wang H
Drug Deliv; 2023 Dec; 30(1):2183821. PubMed ID: 36861451
[TBL] [Abstract][Full Text] [Related]
30. Colonic delivery of celecoxib is a potential pharmaceutical strategy for repositioning the selective COX-2 inhibitor as an anti-colitic agent.
Kim W; Lee Y; Jeong S; Nam J; Lee S; Jung Y
Arch Pharm Res; 2015 Oct; 38(10):1830-8. PubMed ID: 25860026
[TBL] [Abstract][Full Text] [Related]
31. Topical anticolitic efficacy and selectivity of the glucocorticoid budesonide in a new model of acetic acid-induced acute colitis in the rat.
Fabia R; Ar'Rajab A; Willén R; Brattsand R; Erlansson M; Svensjö E
Aliment Pharmacol Ther; 1994 Aug; 8(4):433-41. PubMed ID: 7986968
[TBL] [Abstract][Full Text] [Related]
32. [Locally acting glucocorticoids in chronic intestinal inflammation].
Lamers CB; van der Sluys Veer A; Wagtmans MJ; van Hogezand RA
Ned Tijdschr Geneeskd; 1994 Dec; 138(51):2533-5. PubMed ID: 7830800
[No Abstract] [Full Text] [Related]
33. Oral budesonide therapy for ulcerative colitis: a topical tale.
Feagan BG
Gastroenterology; 1996 Jun; 110(6):2000-2. PubMed ID: 8964430
[No Abstract] [Full Text] [Related]
34. Budesonide-hydroxypropyl-β-cyclodextrin inclusion complex in binary poloxamer 407/403 system for ulcerative colitis treatment: A physico-chemical study from micelles to hydrogels.
Santos Akkari AC; Ramos Campos EV; Keppler AF; Fraceto LF; de Paula E; Tófoli GR; de Araujo DR
Colloids Surf B Biointerfaces; 2016 Feb; 138():138-47. PubMed ID: 26674842
[TBL] [Abstract][Full Text] [Related]
35. Determination of the mitigating effect of colon-specific bioreversible codrugs of mycophenolic acid and aminosugars in an experimental colitis model in Wistar rats.
Chopade SS; Dhaneshwar SS
World J Gastroenterol; 2018 Mar; 24(10):1093-1106. PubMed ID: 29563754
[TBL] [Abstract][Full Text] [Related]
36. Investigation of mitigating effect of colon-specific prodrugs of boswellic acid on 2,4,6-trinitrobenzene sulfonic acid-induced colitis in Wistar rats: Design, kinetics and biological evaluation.
Sarkate A; Dhaneshwar SS
World J Gastroenterol; 2017 Feb; 23(7):1147-1162. PubMed ID: 28275295
[TBL] [Abstract][Full Text] [Related]
37. Topical and oral anti-inflammatory activity of budesonide compared with oral prednisolone in an animal model using allergen-induced gut mucosal exudation of plasma as a marker.
Gustafsson B; Miller-Larsson A; Persson CG
Scand J Gastroenterol; 2001 Oct; 36(10):1062-6. PubMed ID: 11589379
[TBL] [Abstract][Full Text] [Related]
38. Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis.
Naganuma M; Aoyama N; Suzuki Y; Nishino H; Kobayashi K; Hirai F; Watanabe K; Hibi T
J Crohns Colitis; 2016 Jul; 10(7):828-36. PubMed ID: 26577683
[TBL] [Abstract][Full Text] [Related]
39. Treatment of active and postactive ileal and colonic Crohn's disease with oral pH-modified-release budesonide. German Budesonide Study Group.
Caesar I; Gross V; Roth M; Andus T; Schmidt C; Raedsch R; Weber A; Gierend M; Ewe K; Schölmerich J
Hepatogastroenterology; 1997; 44(14):445-51. PubMed ID: 9164517
[TBL] [Abstract][Full Text] [Related]
40. Ciclesonide and budesonide suspensions for nebulization delivery: An in vivo inhalation biopharmaceutics investigation.
Fu TT; Zhao Y; Yang FF; Wen H; Liu CY; Liao YH
Int J Pharm; 2018 Oct; 549(1-2):21-30. PubMed ID: 30048776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
